Survival · adults and children aged over 12 with CF and P aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Antibiotic resistance: change from baseline in P aeruginosa CFU/g of sputum at week 24 · adults and children aged over 12 with CF and P aeruginosa
1 finding from 1 review
Adverse events: number of treatment‐related adverse events · adults and children aged over 12 with CF and P aeruginosa
1 finding from 1 review
Survival: number of deaths · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: anti‐pseudomonal antibiotics showed no clear difference in survival: number of deaths compared with placebo (low certainty).
1 finding from 1 review
FEV1 (% predicted): mean change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pulmonary exacerbations: rate of PDEs per participant year · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: continuous cycles alternating aztreonam lysine… showed no clear difference in pulmonary exacerbations: rate of PDEs per participant year compared with continuous cycles alternating placebo with tobramycin (low certainty).
1 finding from 1 review
Quality of life: respiratory domain · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Survival · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Antibiotic resistance: change from baseline in P aeruginosa CFU/g of sputum at week 24 · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Adverse events: any adverse event in the comparative phase · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: continuous cycles alternating aztreonam lysine… showed no clear difference in adverse events: any adverse event in the comparative phase compared with continuous cycles alternating placebo with tobramycin (low certainty).
1 finding from 1 review
Antibiotic resistance: frequency of tobramycin‐resistant P aeruginosa · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: anti‐pseudomonal antibiotics showed no clear difference in antibiotic resistance: frequency of tobramycin‐resistant P aeruginosa compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
FEV1 (% predicted): mean change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
FVC (% predicted) Change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Intervention not reported
Total studies: 8 RCTs Total Participants: 9983 · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…
1 finding from 1 review
Intervention not reported
Severe exacerbations ‐ MD TRIPLE vs HD‐ICS/LABA№ of participants: 812(1 RCT)
The intervention showed no clear difference in severe exacerbations ‐ MD TRIPLE vs HD‐ICS/LABA№ of participants:… (low certainty).
1 finding from 1 review
Intervention not reported
ACQ responders at 6 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 3063(3 RCTs)
The intervention showed no clear difference in ACQ responders at 6 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of… (low certainty).
1 finding from 1 review
Intervention not reported
ACQ responders at 6 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 1916(2 RCTs)
It is very uncertain whether the intervention changes ACQ responders at 6 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of… (very low certainty).
1 finding from 1 review
Intervention not reported
ACQ responders at 6 months ‐ MD TRIPLE vs HD‐ICS/LABA№ of participants: 2480(2 RCTs)
The intervention showed no clear difference in ACQ responders at 6 months ‐ MD TRIPLE vs HD‐ICS/LABA№ of… (moderate certainty).
1 finding from 1 review